WHO Guideline. Since 2010, countries in the meningitis belt have started to introduce a new serogroup A meningococcal conjugate vaccine conferring individual protection and herd immunity. Following the successful roll-out of this vaccine, epidemics due to Neisseria meningitidis serogroup A (NmA) are... disappearing, but other serogroups (e.g. NmW, NmX and NmC) still cause epidemics, albeit at a lower frequency and of a smaller size. Due to these changes, WHO organized the review of the evidence to provide recommendations for epidemic control, related to operational thresholds for investigation and response to outbreaks, the use of rapid diagnostic tests, antibiotic regimens in epidemics, and prophylaxis for household contacts of cases
more
The scope includes the assessment of activities to improve the response to affected populations, stakeholders, partners and donors, building on lessons learnt so far in this outbreak.
The WHO Health Emergencies Programme is currently monitoring 118 events in the region. This week’s main articles cover the following events:
Coronavirus disease 2019 (COVID-19) in Togo
Measles in Chad
Ebola virus disease (EVD) in Équateur Province, Democratic Republic of the Congo.
Received Date: Jun 15, 2017; Accepted Date: Jun 28, 2017; Published Date: Jun 30, 2017
Citation: Etindele Sosso FA, Nakamura O, Nakamura M (2017) Epidemiology of Alzheimer’s Disease: Comparison between Africa and South America. J Neurol Neurosci Vol.8 No.4:204. DOI: 10.21767/2171-6625.1000204
In the context of the Support to National Malaria Control Programme (SuNMaP), demand creation is the strategic combination of advocacy, communication and mobilisation approaches that seek to achieve increased community awareness of, and demand for, effective malaria prevention and treatment services.... For malaria treatment, demand creation focuses on promoting improved testing, prompt and proper use of artemisinin combination therapy (ACT) treatment for individual cases of malaria, and effective home management of fever, together with referrals of severe cases to a higher-level health facility.
more
PLoS ONE 12(7): e0180996. https://doi.org/10.1371/journal.pone.0180996
PERC produces regional and member state situation analyses, updated regularly.
COVID-19 infection affects all age groups including newborns, however, literature is scarce on the fetal and neonatal outcomes of babies exposed in-utero, especially in Africa. The objectiveof this study was to document the perinatal outcomes of COVID-19 pregnancies and del...iveries that occurredduring the pandemic in Nigeria.
more
Journal of Cancer Education
https://doi.org/10.1007/s13187-020-01935-7
In a retrospective review of hospital records of 40 human monkeypox cases from Nigeria, the majority developed fever and self-limiting vesiculopustular skin eruptions. Five deaths
were reported. Compared to human immunodeficiency virus (HIV)–negative cases, HIV type 1–coinfected cases had more ...prolonged illness, larger lesions, and higher rates of both secondary bacterial skin infections and genital ulcers.
more
The WHO Global Tuberculosis Report 2022 provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of global TB commitments, strategies and targets.
...
The 2022 edition of the report is as usual, based primarily on data gathered by WHO from national ministries of health in annual rounds of data collection. In 2022, 202 countries and territories with more than 99% of the world’s population and TB cases reported data
more
This publication describes the first WHO public-benefit Target Product Profiles (TPPs) for snakebite antivenoms. It focuses on antivenoms for treatment of snakebite envenoming in sub-Saharan Africa. Four TPPs are described in the document:
Broad spectrum Pan-African polyvalent antivenoms: products ...that are intended for widespread utility throughout sub-Saharan Africa for treatment of envenoming irrespective of the species of snake causing a bite. Monovalent antivenoms for specific use cases: for products for a single species (or genus) of snake (e.g., boomslangs or carpet viper antivenoms).
Syndromic Pan-African polyvalent antivenoms for neurotoxic envenoming: products that are intended for treatment of envenoming by species whose venoms are neurotoxic. Syndromic Pan-African polyvalent antivenoms for non-neurotoxic envenoming: products for snakebite envenoming where the effects are largely haemorrhagic, necrotic or procoagulant.
more